- Report
- March 2023
- 209 Pages
Global
From €4247EUR$4,450USD£3,558GBP
- Report
- January 2024
- 200 Pages
Global
From €3961EUR$4,150USD£3,318GBP
- Report
- August 2023
- 145 Pages
Global
From €3006EUR$3,150USD£2,519GBP
- Report
- July 2023
- 128 Pages
North America
From €1432EUR$1,500USD£1,199GBP
- Report
- October 2022
- 232 Pages
Global
From €3436EUR$3,600USD£2,879GBP
- Report
- January 2025
- 93 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- February 2024
- 112 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- October 2024
- 260 Pages
Global
From €2534EUR$2,655USD£2,123GBP
- Report
- May 2023
- 458 Pages
Global
From €3407EUR$3,570USD£2,855GBP
- Book
- June 2024
- 496 Pages
- Book
- April 2023
- 128 Pages
- Book
- November 2022
- 208 Pages
- Book
- December 2019
- 432 Pages
- Book
- December 2019
- 432 Pages
- Book
- January 2019
- 600 Pages
- Book
- January 2019
- 264 Pages
- Book
- March 2018
- 112 Pages
- Book
- May 2014
- 560 Pages
- Book
- April 2014
- 344 Pages
- Book
- April 2013
- 296 Pages

The Bleeding Disorder market is a subset of the Hematology market, which focuses on the diagnosis, treatment, and prevention of blood-related diseases. Bleeding Disorders are a group of conditions that affect the body's ability to control bleeding. These disorders can be caused by a variety of factors, including genetic mutations, acquired conditions, and environmental factors. Common bleeding disorders include hemophilia, von Willebrand disease, and platelet disorders. Treatment for these disorders typically involves the use of clotting factor concentrates, antifibrinolytic agents, and other medications.
The Bleeding Disorder market is highly competitive, with a number of companies offering products and services to treat these conditions. Some of the major players in the market include Novo Nordisk, Pfizer, Bayer, CSL Behring, and Shire. Show Less Read more